Foghorn pulls the plug and trims the team

Oof, that partnership just hit the brakes

Foghorn Therapeutics said it’s discontinuing development of an experimental cancer drug it had partnered with Eli Lilly on after the treatment didn’t show enough benefit in an early-stage trial. Translation: the drug didn’t do enough to justify the next lap around the track.

The kind of news biotech investors dread

This isn’t just a science update — it’s a business reset. Foghorn also said it will cut about 40% of its workforce, which is the corporate version of deciding the airplane is too heavy and tossing out half the luggage mid-flight.

• The drug was in an early-stage trial, so the company was still in the “prove it works” phase.
• Scrapping a partnered asset can hurt pipeline confidence, even if the company isn’t carrying the whole cost alone.
• The layoffs suggest management is trying to protect cash after the setback.

Why you should care

For biotech investors, pipeline misses tend to snowball: less excitement, more caution, and usually a harder look at runway and future financing risk. The Lilly tie-up gave the program some extra credibility, so its failure stings a little more than a solo project going nowhere.

Big picture: this is what happens when the science doesn’t cooperate. The market usually doesn’t mind a pivot — it minds an expensive pivot with fewer shots on goal.